Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.
) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 1.0%. By the end of trading, Biogen Idec rose $10.26 (3.6%) to $295.88 on heavy volume. Throughout the day, 2,705,915 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1,114,200 shares. The stock ranged in a price between $284.51-$297.98 after having opened the day at $286.54 as compared to the previous trading day's close of $285.62. Other companies within the Drugs industry that increased today were:
), up 38.9%,
), up 35.7%,
), up 35.7% and
), up 19.0%.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $59.6 billion and is part of the health care sector. The company has a P/E ratio of 35.5, above the S&P 500 P/E ratio of 17.7. Shares are up 72.5% year to date as of the close of trading on Friday. Currently there are 12 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 6 rate it a hold.
TheStreet Ratings rates
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.
- You can view the full Biogen Idec Ratings Report.
On the negative front,
), down 38.6%,
), down 15.9%,
), down 10.4% and
), down 10.0% , were all laggards within the drugs industry with
) being today's drugs industry laggard.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
) while those bearish on the drugs industry could consider
- Find other investment ideas from our top rated ETFs lists.